Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system
Shuofeng Yuan(University of Hong Kong - Shenzhen Hospital), Kwok‐Yung Yuen(University of Hong Kong - Shenzhen Hospital), Kaiming Tang(University of Hong Kong), Dong‐Yan Jin(University of Hong Kong), Hin Chu(University of Hong Kong), Jasper Fuk‐Woo Chan(Hong Kong Science and Technology Parks Corporation), Jianli Cao(University of Hong Kong), Ronghui Liang(University of Hong Kong), Jian‐Piao Cai(University of Hong Kong), Zi‐Wei Ye(Harbin University of Science and Technology), Kun Wen(Zhujiang Hospital), Gang Lu(Hainan Medical University), Kenn Ka-Hang Chik(University of Hong Kong), Chris Chun-Yiu Chan(University of Hong Kong), Jessica Oi‐Ling Tsang(University of Hong Kong), Lin‐Lei Chen(Queen Mary Hospital)
Cited by 71
Related Papers
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
|The Lancet|2020|9.6k
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
|The Lancet Infectious Diseases|2020|3.4k
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
|Emerging Microbes & Infections|2020|3.3k
Consistent Detection of 2019 Novel Coronavirus in Saliva
|Clinical Infectious Diseases|2020|2k